Nipah Vaccine With ‘Pandemic Potential’ Wins EMA PRIME Designation

The developers of the ChAdOx1 NipahB vaccine will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.

Nipah virus vaccine vial — A vaccine against Nipah virus is being developed by researchers from Oxford University in the UK (Shutterstock)

Key Takeaways

ChAdOx1 NipahB, an investigational vaccine against Nipah virus, has been accepted onto the European Medicines Agency’s priority medicines scheme, PRIME.

An investigational vaccine against Nipah virus infection, a deadly disease said to have pandemic potential, has secured a place on...